What to expect from Obesity Week 2025: Key trends shaping the future of obesity care
October 29, 2025 | Obesity Week, cardiometabolic health
Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.
Authored by: Varun Renjen, Lisa Gallacher, and Brandon Boland
How Inizio experts see the next era of obesity care – and what it means for pharma leadership.
As obesity science continues to evolve, so too does the opportunity for pharma to lead with purpose. Obesity Week 2025 will spotlight this evolution – showcasing how obesity has moved beyond weight loss alone to become a driver of cardiometabolic health.
For Inizio experts Varun Renjen (Partner, Inizio Advisory), Lisa Gallacher (SVP, European Science Lead, Inizio Medical), and Brandon Boland (EVP, Global Biotechnology Portfolio Lead, Inizio Medical), leadership in this fast-changing field means connecting strategy, science, and execution to deliver purposeful progress.
“Obesity has broken out of the shadows of other conferences where it was often an after-thought”,” says Varun Renjen. “This is probably going to be the most relevant conference moving forward for obesity.”
Obesity in the spotlight: From niche to necessity
Once a sub-track at diabetes meetings, Obesity Week has become the premier global congress for this fast-moving therapeutic area.
“It has eclipsed ENDO in priority for our clients,” explains Brandon Boland. “Obesity Week puts obesity in the spotlight.”
That prominence reflects a therapeutic area maturing at pace. Conversations are shifting toward the quality of weight loss versus quantity, the impact on comorbidities, and how new treatment paradigms can deliver sustained outcomes.
“The co-morbidities aspect is key,” adds Lisa Gallacher. “We’re learning more about how obesity therapies can support broader health outcomes – including inflammation, cardiovascular function, and even cognitive health – alongside weight management.”
Evolving science, evolving strategy
As new drug classes expand the landscape – GLP-1s, amylins, dual and multi-agonists – precision medicine and patient segmentation are shaping the next frontier of obesity care.
“The big question is how do we treat such a heterogenous disease within such a large population,” says Varun. “Some will respond better to GLP-1s, others to amylin or dual agonists… a post-menopausal woman will have different clinical needs than a younger man in his 20s. We need to be able to triangulate patient populations and be able to treat more precisely across the whole treatment journey continuum.”
Pharma organizations are also recalibrating commercial strategies around these scientific shifts.
“Clients are vying for patients, trial sites, and share of voice,” says Brandon. “Obesity Week is a chance to gain stature with experts and capture key resources – awareness, asset differentiation, and competitive intelligence all matter.”
Navigating a crowded market with purpose
The obesity market could exceed $100 billion within the decade, but growth brings challenges. Regulatory uncertainty, payer access, and biosimilar pressure are all influencing development and launch decisions.
“There’s regulatory uncertainty in the U.S.,” explains Brandon Boland. “Physicians are balancing how best to integrate weight management and comorbidity care to support overall health and quality of life while maintaining therapy access for their patients.”
“Given how much spend and market demand is anticipated, access will become more challenging,” adds Varun. “But there are creative ways to navigate this through thoughtful portfolio, development, and commercial go to market strategies to ensure a patient can access therapy.”
At Inizio, we help clients simplify this complexity – bringing clarity and cohesion across the full product lifecycle. Our connected approach unites Medical Affairs, strategy, engagement, and technology, enabling teams to move from science to impact.
“It’s about agility in execution,” says Brandon. “Helping clients focus on the mandatories and not get distracted by the noise.”
From obesity to cardiometabolic health
The field’s very definition is expanding.
“The term obesity might evolve over time to cardiometabolic dysfunction,” says Varun. “Treating obesity supports the body from head to toe through one pathway – approvals in kidney, liver, sleep, and even dementia show how interconnected these systems are. Obesity is a complex disease that requires more than a focus on weight reduction – it’s about improving overall metabolic health, as well as preventing and slowing down end organ damage. This is a change of how we think of treating patients not just as treating one disease or one organ but treating the whole patient.”
That shift is echoed across industry communications and R&D focus areas.
“It’s becoming beyond obesity,” adds Lisa. “Clients are reframing around cardio-kidney-metabolic health and other comorbidities. That’s where the conversation is heading.”
And new therapeutic innovations will accelerate it.
“Very soon, multi-agonists will eclipse monotherapies,” predicts Brandon. “Clients need to keep a portfolio approach and not neglect the comorbidities.”
Turning strategy into impact
For Inizio, supporting clients in obesity means helping them anticipate the future – and act on it now.
“We bring full end-to-end development, medical, and commercialization expertise,” says Varun. “And a unified vision of how to own the patient journey across the treatment continuum.”
Whether it’s building purposeful portfolios or shaping the narrative from obesity to cardiometabolic health, Inizio partners to deliver measurable progress. Through Intelligent Commercialization™ – our expert-driven framework connecting data, technology, and AI – we help clients turn scientific innovation into scalable, lasting impact.
As the industry gathers at Obesity Week 2025, we’ll be at booth 812, ready to connect with partners and peers who share our vision of turning science into impact – simplifying complexity, amplifying purpose, and helping clients lead where it matters most.
Get in touch to meet with us at the event or learn more about how we deliver impact across obesity and cardiometabolic health here.
This content was provided by Inizio
Company Details
Latest Content from Inizio
Delivering purposeful solutions at Obesity Week 2025
We’re attending Obesity Week 2025, the world’s leading event dedicated to obesity research and care, to showcase how our integrated expertise is advancing progress in obesity and cardiometabolic health.
Inizio strengthens executive team with new leadership appointments
Inizio has appointed Mary-Kate McGarry as Chief Strategy & Innovation Officer and Gavin McShera as Chief Information Officer, strengthening its executive leadership to drive innovation, digital transformation, and Intelligent Commercialization™...
Inizio celebrates six finalist honors at the 2025 PM360 Trailblazer Awards
Inizio has been named a finalist in six categories at the 2025 PM360 Trailblazer Awards, recognizing its teams’ excellence in AI, data analytics, education, patient engagement, and industry partnership across...
Inizio leaders featured in Forbes’ ‘Voices of Oncology’ to drive innovation in cancer care
Inizio experts contribute to Forbes’ Voices of Oncology, highlighting our commitment to driving innovation in cancer care through advanced data analytics, cross-sector collaboration, and real-world impact for patients.
Inizio appoints Ryan Quigley as CEO
Inizio have appointed Ryan Quigley as Chief Executive Officer, effective 9 September 2025. Paul Taaffe will remain closely involved with the company as an Advisor and board member going forward. ...
What oncologists really want from booth strategy
Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30...
How smart spaces and real-time strategy transformed ASCO® 2025
Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs - it was also a showcase for how technology is redefining congress engagement. Supporting...
The science is shifting in oncology: Are you ready to evolve with it?
Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke. This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic...
Reimagine health with Inizio.
At Inizio, we provide tailored, innovative solutions to help health and life sciences companies with their clinical development and commercialization journeys, maximizing patient access. Our experts guide you through each...
Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development
Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...